Compositions and methods for enhancing drug delivery across and into epithelial tissues
View Patent ↗This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
1. A method of enhancing delivery of a compound across the blood-brain barrier of an animal, the method comprising
contacting the blood-brain barrier with a conjugate consisting of the compound and a delivery-enhancing transporter, at a concentration effective for delivering a therapeutically effective amount across the blood-brain barrier,
wherein the delivery-enhancing transporter consists of 5 to 50 amino acids that comprises 5 to 25 arginine residues or analogs thereof, thereby increasing delivery of the conjugate across the blood-brain barrier compared to delivery of the compound in the absence of the delivery-enhancing transporter, and
wherein the conjugate has a structure selected from the group consisting of structures 3, 4, and 5, as follows:
wherein:
R 1 comprises the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
A is N or CH;
R 2 is hydrogen, alkyl, aryl, acyl, or allyl;
R 3 comprises the delivery-enhancing transporter;
R 4 is S, O, NR 6 or CR 7 R 8 ;
R 5 is H, OH, SH or NHR 6 ;
R 6 is hydrogen, alkyl, aryl, acyl or allyl;
R 7 and R 8 are independently selected from hydrogen or alkyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10.
2. The method of claim 1 , wherein delivery of the conjugate across the blood-brain barrier is increased at least two-fold compared to delivery of the compound in the absence of the delivery-enhancing transporter.
3. The method of claim 1 , wherein delivery of the conjugate across the blood-brain barrier is increased at least ten-fold compared to delivery of the compound in the absence of the delivery-enhancing transporter.
4. The method of claim 1 , wherein X is selected from the group consisting of —C(O)O—, —C(O)NH—, —OC(O)NH—, —S—S—, —C(S)O—, —C(S)NH—, —NHC(O)NH—, —SO 2 NH—, —SONH—, phosphate, phosphonate, phosphinate, and CR 7 , R 8 , wherein R 7 and R 8 are each independently selected from the group consisting of H and alkyl.
5. The method of claim 1 , wherein the conjugate comprises structure 3, Y is NH, and R 2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.
6. The method of claim 1 , wherein R 2 is benzyl; k, m, and n are each 1, and X is —OC(O)—.
7. The method of claim 1 , wherein the conjugate comprises structure 4; R 4 is S; R 5 is NHR 6 ; and R 6 is hydrogen, methyl, allyl, butyl or phenyl.
8. The method of claim 1 , wherein the conjugate comprises structure 4; R 5 is NHR 6 ; R 6 is hydrogen, methyl, allyl, butyl or phenyl; and k and m are each 1.
9. A method of enhancing delivery of a compound across the blood-brain barrier of an animal, the method comprising
contacting the blood-brain barrier with a conjugate comprising the compound and a delivery-enhancing transporter, at a concentration effective for delivering a therapeutically effective amount across the blood-brain barrier,
wherein the delivery-enhancing transporter consists of 5 to 50 amino acids that comprises 5 to 25 arginine residues or analogs thereof, thereby increasing delivery of the conjugate across the blood-brain barrier compared to delivery of the compound in the absence of the delivery-enhancing transporter, and
wherein the conjugate comprises structure 6 as follows:
wherein:
R 1 comprises the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
R 3 comprises the delivery-enhancing transporter;
R 4 is S, O, NR 6 or CR 7 , R 8 ;
R 5 is H, OH, SH or NHR 6 ;
R 6 is hydrogen, alkyl, aryl, arylalkyl, acyl or allyl;
R 7 and R 8 are independently selected from hydrogen or alkyl; and
k and m are each independently selected from 1 and 2.
10. The method of claim 9 , wherein X is selected from the group consisting of —C(O)O—, —C(O)NH—, —OC(O)NH—, —S—S—, —C(S)O—, —C(S)NH—, —NHC(O)NH—, —S0 2 NH—, —SONH—, phosphate, phosphonate phosphinate, and CR 7 , R 8 , wherein R 7 and R 8 are each independently selected from the group consisting of H and alkyl.
11. The method of claim 9 , wherein R 4 is S; R 5 is NHR 6 ; and R 6 is hydrogen, methyl, allyl, butyl or phenyl.
12. A method of enhancing delivery of a compound across the blood-brain barrier of an animal, the method comprising
contacting the blood-brain barrier with a conjugate consisting of the compound and at least two delivery-enhancing transporters, at a concentration effective for delivering a therapeutically effective amount across the blood-brain barrier,
wherein each of the at least two delivery-enhancing transporter consists of 5 to 50 amino acids that comprises 5 to 25 arginine residues or analogs thereof, thereby increasing delivery of the conjugate across the blood-brain barrier compared to delivery of the compound in the absence of the delivery-enhancing transporter, and
wherein the conjugate has a structure selected from the group consisting of structures 3, 4, and 5, as follows:
wherein:
R 1 comprises the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
A is N or CH;
R 2 is hydrogen, alkyl, aryl, acyl, or allyl;
R 3 comprises the delivery-enhancing transporter;
R 4 is S, O, NR 6 or CR 7 R 8 ;
R 5 is H, OH, SH or NHR 6 ;
R 6 is hydrogen, alkyl, aryl, acyl or allyl;
R 7 and R 8 are independently selected from hydrogen or alkyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10.
13. The method of claim 1 , wherein at least one arginine is a D-arginine.
14. The method of claim 1 , wherein all of the arginines are D-arginines.
15. The method of claim 1 , wherein at least 70 percent of the amino acids that comprise the delivery-enhancing transporter are arginines or arginine analogs.
16. The method of claim 1 , wherein the delivery-enhancing transporter is seven contiguous D-arginines.
17. The method of claim 1 , wherein the compound is a therapeutic agent.
18. The method of claim 1 , wherein the compound is a diagnostic agent.
19. The method of claim 1 , wherein the compound is an antibody or an antibody fragment.
20. The method of claim 1 , wherein the compound is a therapeutic protein.
21. The method of claim 1 , wherein the conjugate is administered intravenously, topically, subcutaneously, transcutaneously, intramuscularly, orally, buccally, at an intra-joint site, parenterally, peritoneally, intranasally, by inhalation, or via administration to or at the skin, lungs, gastrointestinal tract, anal region, vagina, eye, or ear.
22. The method of claim 21 , wherein the conjugate is administered intravenously.
23. The method of claim 21 , wherein the conjugate is administered subcutaneously.
24. The method of claim 21 , wherein the conjugate is administered topically.
25. The method of claim 24 , wherein the conjugate is administered transdermally.